Ambrx Biopharma American Financials

Ambrx Biopharma Stock Summary

Ambrx Biopharma competes with Immix Biopharma, Cns Pharmaceuticals, Sonnet Biotherapeutics, Enveric Biosciences, and Elevation Oncology. Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company was incorporated in 2003 and is headquartered in La Jolla, California. Ambrx Biopharma operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 81 people.

Ambrx Biopharma Key Financial Ratios

Ambrx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Ambrx Biopharma's current stock value. Our valuation model uses many indicators to compare Ambrx Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ambrx Biopharma competition to find correlations between indicators driving Ambrx Biopharma's intrinsic value. More Info.Ambrx Biopharma American is rated below average in return on equity category among its peers. It is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Ambrx Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.